2026-04-13T01:42:10Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/2041232024-11-29T10:35:00Zcom_2072_1057col_2072_478917col_2072_478921
RECERCAT
author
Santos Bravo, Marta
author
Nicolas Plault
author
Sánchez Palomino, Sonsoles
author
Rodríguez, Cristina
author
Navarro Gabriel, Mireia
author
Mosquera, María Mar
author
Fernández Avilés, Francesc
author
Suarez Lledó, María
author
Rovira, Montserrat
author
Bodro, Marta
author
Moreno Camacho, Ma. Asunción
author
Linares, Laura
author
Cofán Pujol, Federico
author
Berengua, Carla
author
Esteva, Cristina
author
Cordero, Elisa
author
Martín Dávila, Pilar
author
Aranzamendi, Maitane
author
Pérez Jiménez, Ana Belén
author
Vidal, Elisa
author
Fernández Sabé, Núria
author
Len, Óscar
author
Hantz, Sebastien
author
Alain, Sophie
author
Marcos, Ma. Angeles
author
the Spanish Network for Research in Infectious Diseases (REIPI)
author
Group for the Study of Infection in Transplantation (GESITRA)
2024-11-29T10:35:00Z
2024-11-29T10:35:00Z
2023-12-04T18:21:55Z2023-12-04T18:21:55Z2022-11-012023-12-04T18:21:55Z
http://hdl.handle.net/2445/204123
Background This study describes the genotypic and phenotypic characterization of novel human cytomegalovirus (HCMV) genetic variants of a cohort of 94 clinically resistant HCMV patients. Methods and results Antiviral-resistant mutations were detected in the UL97, UL54, and UL56 target genes of 25 of 94 (26.6%) patients. The genotype-phenotype correlation study resolved the status of 5 uncharacterized UL54 deoxyribonucleic acid polymerase (G441S, A543V, F460S, R512C, A928T) and 2 UL56 terminase (F345L, P800L) mutations found in clinical isolates. A928T conferred high, triple resistance to ganciclovir, foscarnet, and cidofovir, and A543V had 10-fold reduced susceptibility to cidofovir. Viral growth assays showed G441S, A543V, F345L, and P800L impaired viral growth capacities compared with wild-type AD169 HCMV. Three-dimensional modeling predicted A543V and A928T phenotypes but not R512C, reinforcing the need for individual characterization of mutations by recombinant phenotyping. Conclusions Extending mutation databases is crucial to optimize treatments and to improve the assessment of patients with resistant/refractory HCMV infection.
(c) Marta Santos Bravo et al., 2022 info:eu-repo/semantics/openAccess
Citomegalovirus
Resistència als medicaments
Cytomegaloviruses
Drug resistance
Genotypic and phenotypic study of antiviral resistance mutations in refractory cytomegalovirus infection
info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion